Opus Genetics Gets FDA Clearance to Test OPGx-RDH12 Gene Therapy

• FDA cleared Opus Genetics' investigational new drug application for OPGx-RDH12, a gene therapy targeting RDH12-associated Leber congenital amaurosis.
• A Phase 1/2 trial is planned to begin this quarter for the inherited retinal disease, which causes childhood vision loss.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Opus Genetics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610210700PRIMZONEFULLFEED9849667) on October 21, 2026, and is solely responsible for the information contained therein.